Table 1.
CYP1A2 expression in mouse and rat liver upon CS and THS (M) exposuresss.
| CYP1A2 expression in the liver | CS |
THS with HEETS (M) |
CESS/SWITCH |
||||||
|---|---|---|---|---|---|---|---|---|---|
| Group1 | FC2 mRNA | FC2 protein | Group1 | FC2 mRNA | FC2 protein | Group1 | FC2 mRNA | FC2 protein | |
| ApoE−/− mouse study #1 | 3R4F 6m | 1.39 | 1.60* | THS 6m | 1.05 | 0.96 | CESS 6m | 1.04 | 1.01 |
| 3R4F 8m | 1.44 | 1.76* | THS 8m | 1.11 | 1.00 | CESS 8m | 1.07 | 1.00 | |
| SWITCH 6m | 1.05 | 1.02 | |||||||
| SWITCH 8m | 1.09 | 1.01 | |||||||
| ApoE−/− mouse study #2 | 3R4F 6m | 1.35* | 1.38* | THS2.2 6m | 1.06 | 1.05 | CESS 6m | 1.02 | 0.97 |
| OECD 90-day rat THS2.2 | 3R4F-23-F-90d | 1.11 | THS2.2−23-F-90d | 1.07 | |||||
| 3R4F-23-M-90d | 1.90 | THS2.2−23-M-90d | 1.25 | ||||||
| OECD 90-day rat THS2.2M | 3R4F-23-F-90d | 1.37 | 1.33 | THS M-23-F-90d | 0.86 | 1.07 | |||
| 3R4F-23-M-90d | 1.58 | 1.23 | THS M-23-M-90d | 1.19 | 1.12 | ||||
| 1XMIS-23-F-90d | 1.44 | 1.38 | |||||||
| 1XMIS-23-M-90d | 1.52 | 1.30* | |||||||
| 2XMIS-23-F-90d | 1.45* | 1.33* | |||||||
| 2XMIS-23-M-90d | 1.59 | 1.25 | |||||||
Bold values represent statistically significant results.
Included studies: ApoE-/- mouse study #1 [24], ApoE-/- mouse study #2 [25], OECD 90-day rat THS [28], and OECD 90-day rat THS mentholated [26,27].
Group labels: Item–Time point (mouse studies), Item–Concentration (μg nicotine/L)–Sex (M (male), F (female))–Time point (rat studies), CESS, cessation, SWITCH, switching from 3R4F CS to THS aerosol.
Sample sizes: N = 8 (ApoE-/- mouse study #1, mRNA), N = 8 (ApoE-/- mouse study #1, protein), N = 9 (ApoE-/- mouse study #2, mRNA), N = 8 (ApoE-/- mouse study #2, protein), N = 6 (OECD 90-day rat THS2.2, mRNA), N = 6 (OECD 90-day rat THS2.2 M, mRNA), N = 6 (OECD 90-day rat THS2.2 M, protein).
Group comparisons versus animals exposed to fresh air labeled as Item.
Expression fold changes versus animals exposed to fresh air.
False discovery rate-adjusted p value < 0.05. The false-discovery rate represents the proportion of false discoveries after adjustment for multiple-hypotheses testing of the evaluated omics data.